# OnCo record advanced-recurrent-endometrial-cancer (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/advanced-recurrent-endometrial-cancer/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "advanced-recurrent-endometrial-cancer" ;
  schema:name "Advanced or recurrent endometrial cancer"@en ;
  schema:alternateName "Stage III to IV endometrial cancer"@en, "Metastatic endometrial cancer"@en, "Relapsed endometrial cancer"@en, "Primary advanced endometrial cancer"@en ;
  schema:description "Advanced or recurrent endometrial cancer has spread beyond the uterus or come back after treatment. Chemotherapy plus an immune checkpoint antibody is now the first treatment for everyone, with the biggest gains in mismatch-repair-deficient tumours, and lenvatinib with pembrolizumab is the standard when platinum chemotherapy stops working."@en ;
  schema:url <https://onco.cc/cancers/advanced-recurrent-endometrial-cancer/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Endometrial_cancer> ;
  schema:citation <https://en.wikipedia.org/wiki/Endometrial_cancer> ;
  onco:tag "subtype-page" ;
  onco:pipeline <https://onco.cc/drugs/sacituzumab-tirumotecan/>, <https://onco.cc/drugs/rinatabart-sesutecan/>, <https://onco.cc/trials/rainfol-01/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/trials/nct06989112/>, <https://onco.cc/trials/nct05173987/>, <https://onco.cc/drugs/luveltamab-tazevibulin/>, <https://onco.cc/drugs/saruparib/>, <https://onco.cc/drugs/abemaciclib/> ;
  onco:standardOfCare <https://onco.cc/drugs/dostarlimab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/trials/ruby/>, <https://onco.cc/trials/nrg-gy018-keynote-868/>, <https://onco.cc/pairings/chemo-io-first-line-endometrial/>, <https://onco.cc/terms/msi/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/dostarlimab/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/trials/duo-e/>, <https://onco.cc/drugs/trastuzumab/>, <https://onco.cc/terms/mss-pmmr/>, <https://onco.cc/drugs/lenvatinib/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/trials/keynote-775/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/trials/destiny-pantumor02/>, <https://onco.cc/drugs/letrozole/>, <https://onco.cc/drugs/megestrol-progestins/>, <https://onco.cc/drugs/dostarlimab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/brachytherapy/>, <https://onco.cc/terms/radiotherapy/> .